Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Truist Securities Maintains Buy on Biogen, Raises Price Target to $350

Truist Securities analyst Robyn Karnauskas maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $265 to $350.
byBenzinga Newsdesk
November 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Truist Securities analyst Robyn Karnauskas maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $265 to $350.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0